Email: cspc@cspc.cn
Media
News Center
Mar. 29
2024
Results of a Phase III Clinical Study on Batoclimab of CSPC Published in JAMA Sub-journal
Mar. 25
VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
VOLUNTARY ANNOUNCEMENT SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
Mar. 21
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Mar. 19
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Mar. 15
CSPC Innovation Included in FTSE Global Equity Index Series
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
